Prognosis
CDC Adviser Sees Potential for Longer Pause on J&J Vaccine
- Hold could stretch out for weeks as more data are collected
- Advisory panel to reconvene late next week to weigh resumption
This article is for subscribers only.
A hold on the use of Johnson & Johnson’s Covid-19 vaccine in the U.S. could stretch out for several weeks, according to the head of an advisory panel that is expected to make a recommendation about whether shots should resume.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is weighing the scientific evidence after reports that six people who received the vaccine subsequently suffered rare blood clots in the brain. Earlier this week, U.S. regulators ordered a temporary halt in use of the shot.